Uveitis Drugs Market by Product and Geography - Forecast and Analysis 2022-2026

The uveitis drugs market share is expected to increase to USD 269.65 million from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 5.9%.

This uveitis drugs market research report provides valuable insights on the post COVID-19 impact on the market, which will help companies evaluate their business approaches. Furthermore, this report extensively covers uveitis drugs market segmentation by product (small molecules and biologics) and geography (North America, Europe, Asia, and Rest of World (ROW)). The uveitis drugs market report also offers information on several market vendors, including AbbVie Inc., Alimera Sciences Inc., Amgen Inc., Aurobindo Pharma Ltd., Bausch Health Companies Inc., Biogen Inc., Cadila Pharmaceuticals Ltd., EyePoint Pharmaceuticals Inc., Hikma Pharmaceuticals Plc, Horizon Therapeutics Plc, Johnson and Johnson, Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., Santen Pharmaceutical Co. Ltd., Sebela Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd. among others.

What will the Uveitis Drugs Market Size be During the Forecast Period?

Download the Free Report Sample to Unlock the Uveitis Drugs Market Size for the Forecast Period and Other Important Statistics

 

Uveitis Drugs Market: Key Drivers, Trends, and Challenges

Based on our research output, there has been a neutral impact on the market growth during and post COVID-19 era. The high prevalence of eye disorders and associated risk factors of uveitis is notably driving the uveitis drugs market growth, although factors such as adverse effects of corticosteroids may impede market growth. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic impact on the uveitis drugs industry. The holistic analysis of the drivers will help in deducing end goals and refining marketing strategies to gain a competitive edge.

Key Uveitis Drugs Market Driver

• One of the key factors driving the global uveitis drugs market growth is the high prevalence of eye disorders and associated risk factors of uveitis.
• According to WHO, approximately 1 billion people have moderate or severe distance vision impairment or blindness globally due to unaddressed refractive error.
• Uveitis has multifactorial etiologies, which consist of attacks from the body's immune system, infections, or tumors occurring within the eye or in other parts of the body.
• The condition could also occur due to bruises in and around the eye and toxins that may penetrate the eye.
• People with AIDS, rheumatoid arthritis, multiple sclerosis, TB, and syphilis have higher chances of contracting the eye condition.
• Prevalence of other risk factors including hepatitis, Bechet's syndrome, cytomegalovirus retinitis, psoriasis, and ulcerative colitis will drive the growth of the market during the forecast period.

Key Uveitis Drugs Market Trend

• Development of gene therapy is one of the key industrial market trends that is expected to impact the industry positively in the forecast period.
• The side effects of small molecule drugs have led pharmaceutical companies to shift their focus to gene therapy, uveitis drugs, and other biologics.
• Gene therapy for uveitis offers the possibility of potent, self-regulating, and long-term disease control following a single treatment.
• On June 1, 2022, the NIH-funded clinical trial on gene therapy for rare eye diseases showed benefits for patients diagnosed with Leber hereditary optic neuropathy.
• Gene therapy approaches using interleukin-10, interleukin-1 receptor antagonist, soluble TNF-alpha receptors, and alpha-melanocyte-stimulating hormone gene transfer have successfully exhibited efficacy in the preclinical trials for the treatment of uveitis.
• Eyevensys S.A.S. is using EYS606, a clinical-grade plasmid DNA, for the electrotransfer of EYS606 in the ciliary muscle.
• The increase in R&D by market vendors will further support the growth of the uveitis drugs market in the forecast years.

Key Uveitis Drugs Market Challenge

• One of the key challenges to the global industrial market growth is the adverse effects of corticosteroids.
• The drugs such as corticosteroids demonstrate a range of adverse effects such as fatigue, muscle cramps, nausea, vomiting, and diarrhea.
• The drugs may even trigger or worsen eye disorders such as uveitis.
• The adverse effects of OZURDEX include blurred vision, eye inflammation, increased eye pressure, increased sensitivity of the eyes to light or vision changes, and retinal detachment.
• Corticosteroids and some off-label drugs, which are used for treating uveitis and various ophthalmology indications, are associated with a spectrum of adverse effects.
• The side effects adversely affect patient adherence to treatments, which may hinder the market growth during the forecast period.

This uveitis drugs market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2022-2026.

Parent Market Analysis

Technavio categorizes the global uveitis drugs market as a part of the global pharmaceuticals market. Our research report has extensively covered external factors influencing the parent market growth potential in the coming years, which will determine the levels of growth of the uveitis drugs market during the forecast period.

Who are the Major Uveitis Drugs Market Vendors?

The report analyzes the market's competitive landscape and offers information on several market vendors, including:

 

• AbbVie Inc.
• Alimera Sciences Inc.
• Amgen Inc.
• Aurobindo Pharma Ltd.
• Bausch Health Companies Inc.
• Biogen Inc.
• Cadila Pharmaceuticals Ltd.
• EyePoint Pharmaceuticals Inc.
• Hikma Pharmaceuticals Plc
• Horizon Therapeutics Plc
• Johnson and Johnson
• Novartis AG
• Pfizer Inc.
• Regeneron Pharmaceuticals Inc.
• Santen Pharmaceutical Co. Ltd.
• Sebela Pharmaceuticals Inc.
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceutical Industries Ltd.

 

This statistical study of the uveitis drugs market encompasses successful business strategies deployed by the key vendors. The uveitis drugs market is fragmented and the vendors are deploying growth strategies such as investment in R&D to compete in the market.

Product Insights and News

• AbbVie Inc. - The company offers delta robots under the brand name FlexPacker, designed for rapid changeover times that accompany the growth of low volume, high mix production to respond to the revolution of new consumer demands.
• Alimera Sciences Inc. - The company offers delta robots that are assembled and ready to control plants with integrated cameras and controllers for robotics and automation laboratories.

To make the most of the opportunities and recover from post COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.

The uveitis drugs market forecast report offers in-depth insights into key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies.

Uveitis Drugs Market Value Chain Analysis

Our report provides extensive information on the value chain analysis for the uveitis drugs market, which vendors can leverage to gain a competitive advantage during the forecast period. The end-to-end understanding of the value chain is essential in profit margin optimization and evaluation of business strategies. The data available in our value chain analysis segment can help vendors drive costs and enhance customer services during the forecast period.

Which are the Key Regions for Uveitis Drugs Market?

For more insights on the market share of various regions Request for a FREE sample now!

43% of the market's growth will originate from North America during the forecast period. US and Canada are the key markets for uveitis drugs in North America. Market growth in this region will be faster than the growth of the market in Europe and ROW.

The significant increase in the sales of approved drugs for the treatment of uveitis and the increasing prevalence of several associated risk factors for the condition will facilitate the uveitis drugs market growth in North America over the forecast period. This market research report entails detailed information on the competitive intelligence, marketing gaps, and regional opportunities in store for vendors, which will assist in creating efficient business plans.

COVID Impact and Recovery Analysis

The COVID-19 pandemic had a negative impact on the growth of the regional uveitis drugs market in 2020. The pandemic led to a decline in the use of uveitis drugs in regional healthcare facilities due to the temporary suspension of ophthalmologic diagnostic services as well as procedures. However, the initiation of COVID-19 vaccination drives from December 2020 and the subsequent lifting of lockdown restrictions led to the gradual resumption of operations in pharmaceutical manufacturing and logistics units, which helped in easing R&D-related constraints. Therefore, the regional uveitis drugs market is expected to witness growth during the forecast period.

What are the Revenue-generating Product Segments in the Uveitis Drugs Market?

To gain further insights on the market contribution of various segments Request for a FREE sample

The uveitis drugs market share growth by the small molecules segment will be significant during the forecast period. Small molecules are synthesized by chemical reactions between different organic and/or inorganic compounds. Corticosteroids such as prednisone (RAYOS), dexamethasone (DECADRON), and methylprednisolone (MEDROL) are largely used to treat uveitis. The increased use of corticosteroids for the treatment of uveitis, owing to the easy availability and low cost of corticosteroid generics, will drive the growth of the segment in focus in the coming years.

This report provides an accurate prediction of the contribution of all the segments to the growth of the uveitis drugs market size and actionable market insights on post COVID-19 impact on each segment.

 

Uveitis Drugs Market Scope
Report Coverage	Details
Page number	120
Base year	2021
Forecast period	2022-2026
Growth momentum & CAGR	Accelerate at a CAGR of 5.9%
Market growth 2022-2026	$ 269.65 million
Market structure	Fragmented
YoY growth (%)	5.3
Regional analysis	North America, Europe, Asia, and Rest of World (ROW)
Performing market contribution	North America at 43%
Key consumer countries	US, Canada, Germany, UK, and China
Competitive landscape	Leading companies, Competitive strategies, Consumer engagement scope
Key companies profiled	AbbVie Inc., Alimera Sciences Inc., Amgen Inc., Aurobindo Pharma Ltd., Bausch Health Companies Inc., Biogen Inc., Cadila Pharmaceuticals Ltd., EyePoint Pharmaceuticals Inc., Hikma Pharmaceuticals Plc, Horizon Therapeutics Plc, Johnson and Johnson, Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., Santen Pharmaceutical Co. Ltd., Sebela Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd.
Market dynamics	Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period
Customization purview	If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Request for a FREE sample

What are the Key Data Covered in this Uveitis Drugs Market Report?

• CAGR of the market during the forecast period 2022-2026
• Detailed information on factors that will drive uveitis drugs market growth during the next five years
• Precise estimation of the uveitis drugs market size and its contribution to the parent market
• Accurate predictions on upcoming trends and changes in consumer behavior
• The growth of the uveitis drugs industry across North America, Europe, Asia, and Rest of World (ROW)
• A thorough analysis of the market's competitive landscape and detailed information on vendors
• Comprehensive details of factors that will challenge the growth of uveitis drugs market vendors

We can help! Our analysts can customize this report to meet your requirements. Get in touch